Ventyx Biosciences Inc
A clinical-stage biopharmaceutical company developing small-molecule therapies for inflammatory and autoimmune diseases, including a potential oral treatment for ulcerative colitis and Crohn's disease. Founded by biotech entrepreneur and named for the Ventyx of Greek mythology. Note: The grounding search service was unavailable (HTTP 502) during this attempt, so this description could not be verified against web sources and should be treated with caution.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT, LLC | 13G/APassive | 0% | 0 | May 15, 2026 |
| KEVIN TANG | 13G/APassive | 0% | 0 | May 15, 2026 |
| TANG CAPITAL PARTNERS, LP | 13G/APassive | 0% | 0 | May 15, 2026 |
| TANG CAPITAL PARTNERS INTERNATIONAL, LP | 13G/APassive | 0% | 0 | May 15, 2026 |
| TANG CAPITAL PARTNERS III, INC | 13G/APassive | 0% | 0 | May 15, 2026 |
| TANG CAPITAL PARTNERS IV, INC | 13G/APassive | 0% | 0 | May 15, 2026 |
| Affinity Asset Advisors, LLC | 13G/APassive | 0% | 0 | May 14, 2026 |
| Michael Cho | 13G/APassive | 0% | 0 | May 14, 2026 |
| Glazer Capital, LLC | 13G/APassive | 0% | 0 | May 14, 2026 |
| Paul J. Glazer | 13G/APassive | 0% | 0 | May 14, 2026 |